Total revenue increased 7% to a record $11.0M from $10.2M in the same prior year period. During 2026, the Company has reduced ...

ArriVent BioPharma, Inc. announced initial Phase 1 results for ARR-217 (MRG007), a cadherin-17-targeting antibody-drug conjugate developed in partnership with Lepu Biopharma Co., Ltd. The data, ...

These leaders in cybersecurity, data analytics, and servers are benefiting from growth in AI spending.

The TCW Concentrated Large Cap Growth Fund Q3 2026 Commentary details tech sector performance and strategic stock holdings.

We open with four things to look for in the Anthropic IPO filing, which could be public next week. Plus, we cover a bank note ...

ArriVent BioPharma (NASDAQ:AVBP) delivered early oncology updates with initial Phase 1 results for ARR-217, an investigational antibody-drug conjugate targeting cadherin-17 (CDH17). The candidate, ...

The investment thesis hinges on MNDY's ability to scale operating expenses down to 75% of revenue by 2031, not just AI credit ...

AudioEye Q3 2026 revenue reached a record $11 million as adjusted EBITDA rose 58%. Management raised full-year EBITDA ...

In addition, it’s important that synergies are measurable. According to the PwC deals survey, 62% of successful acquirers ...

One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...

ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR PRC) (“ARMOUR” or the “Company”) today announced the Company's unaudited Q3 results and September 30, 2026 financial position. Q3 2026 Results ...